Acute lymphoblastic leukaemia trials in United States

In United States 232 Also abroad 564

232 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
Blinatumomab Consolidation in Real World
Where
Chicago, Jacksonville, Milwaukee, Philadelphia
Age
18 years and over
People
200
Run by
Medical College of Wisconsin
See details and how to joinNCT07117136
Phase 1Taking people
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Where
Atlanta, Columbus, Duarte, Hackensack, Houston, Kansas City, Milwaukee, New York, Sacramento, Seattle, Stanford, Tampa
Age
12 years to 78 years
People
300
Run by
Orca Biosystems, Inc.
See details and how to joinNCT03802695
Phase 2Taking people
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Where
Atlanta, Cincinnati, Denver, Duarte, Houston, Los Angeles, Nashville, New York, Norfolk, Philadelphia, San Antonio, Seattle, St Louis, Tampa, Washington D.C.
Age
6 months and over
People
125 worldwide
Run by
Allotera Therapeutics
See details and how to joinNCT06514794
Phase 2Taking people
Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Where
Tampa
Age
18 years and over
People
60
Run by
H. Lee Moffitt Cancer Center and Research Institute
See details and how to joinNCT06144606
No phaseTaking people
Evaluating the Relationship Between Skin Color and Pulse Oximeter Accuracy in Children
Where
Houston, New York, Philadelphia
Age
4 weeks to 18 years
People
650
Run by
University of Pennsylvania
See details and how to joinNCT06529575
Phase 2Taking people
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
Where
Houston
Age
1 year to 25 years
People
27
Run by
M.D. Anderson Cancer Center
See details and how to joinNCT05645718
Phase 2Taking people
A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
Where
Houston
Age
1 month to 21 years
People
22
Run by
M.D. Anderson Cancer Center
See details and how to joinNCT06561074
No phaseTaking people
Imaging Skeletal Muscle Mitochondrial OXPHOS Activity In Acute Lymphoblastic Leukemia Survivors
Where
Memphis
Age
18 years and over
People
60
Run by
St. Jude Children's Research Hospital
See details and how to joinNCT06819475
Phase 2Taking people
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
Where
Chicago
Age
18 years and over
People
20
Run by
Eastern Cooperative Oncology Group
See details and how to joinNCT05289687
Phase 1Taking people
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
Where
Memphis
Age
Up to 25 years
People
29
Run by
St. Jude Children's Research Hospital
See details and how to joinNCT06810583
Phase 2Taking people
Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
Where
Cleveland
Age
18 years and over
People
36
Run by
Case Comprehensive Cancer Center
See details and how to joinNCT06904482
Phase 1/2Taking people
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
Where
Aurora
Age
31 days to 30 years
People
45
Run by
University of Colorado, Denver
See details and how to joinNCT04544592
Phase 2Not yet taking people in United States
Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome
Where
Seattle
People
52
Run by
Fred Hutchinson Cancer Center
See details and how to joinNCT07819396
Phase 1Taking people
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma
Where
Aurora, Boston, Columbus, Gainsville, Grand Rapids, Houston, Indianapolis, Loma Linda, Los Angeles, Milwaukee, Philadelphia, Phoeniz, San Francisco, St. Petersburg, Vallhala, Washington D.C.
Age
Up to 39 years
People
30
Run by
New York Medical College
See details and how to joinNCT04972942
Phase 1Not yet taking people in United States
Study Of KITE-753 in R/R B-Cell ALL
Where
Houston
Age
18 years and over
People
18
Run by
M.D. Anderson Cancer Center
See details and how to joinNCT07674823
Phase 1/2Taking people
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
Where
Boston, Cleveland, Columbus, New York, Omaha, Westwood
Age
16 years to 75 years
People
44
Run by
Leland Metheny
See details and how to joinNCT03104491
No phaseNot yet taking people in United States
VR-PAT and fNIRS to Identify CNS Biomarkers of Pain
Where
Columbus
Age
6 years to 17 years
People
4
Run by
Nationwide Children's Hospital
See details and how to joinNCT06303687
Phase 1Taking people
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Where
Atlanta, Baltimore, Boston, Dallas, Milwaukee, Minneapolis, New York, Providence, Tampa
Age
18 years and over
People
135 worldwide
Run by
Imugene Limited
See details and how to joinNCT03666000
Phase 2Taking people
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Where
Akron, Albany, Albuquerque, Allentown, Anaheim, Anchorage, Ann Arbor, Arroyo Grande, Asheville, Atlanta, Aurora, Austin, Baltimore, Bangor, Battle Creek, Bellevue, Bellflower, Bethesda, Birmingham, Boise, Boston, Bridgeport, Brooklyn, Burlington, Carson City, Chapel Hill, Charleston, Charlotte, Chicago, Cincinnati, Cleveland, Columbia, Columbus, Corpus Christi, Dallas, Danville, Dayton, Dearborn, Denver, Des Moines, Detroit, Downey, Duarte, Durham, East Lansing, El Paso, Falls Church, Fargo, Fontana, Fort Myers, Fort Worth, Gainesville, Grand Rapids, Green Bay, Greenville, Hackensack, Hartford, Henderson, Hershey, Hollywood, Honolulu, Houston, Indianapolis, Iowa City, Jackson, Jacksonville, Kalamazoo, Kansas City, Kingman, Knoxville, Las Vegas, Lebanon, Lexington, Little Rock, Loma Linda, Long Beach, Los Angeles, Louisville, Lubbock, Madera, Madison, Martinsburg, Maywood, Mesa, Milwaukee, Mineola, Minneapolis, Mobile, Morgantown, Morristown, Muskegon, Nashville, Newark, New Brunswick, New Hyde Park, New Orleans, New York, Niles, Norfolk, Norton Shores, Oakland, Oklahoma City, Omaha, Orange, Orlando, Pahrump, Palo Alto, Parkersburg, Paterson, Pensacola, Peoria, Philadelphia, Phoenix, Pittsburgh, Portland, Providence, Reed City, Reno, Renton, Richmond, Rochester, Royal Oak, Sacramento, Saint Joseph, Salt Lake City, San Antonio, San Diego, San Francisco, Savannah, Scarborough, Seattle, Sioux Falls, Spokane, St Louis, Stony Brook, St. Petersburg, Sylvania, Syracuse, Tacoma, Tampa, The Bronx, Toledo, Torrance, Traverse City, Troy, Tucson, Tulsa, Washington D.C., West Palm Beach, Wilmington, Winston-Salem, Wyoming, Yakima
Age
1 year to 30 years
People
461 worldwide
Run by
National Cancer Institute (NCI)
See details and how to joinNCT04546399
Phase 1Taking people
Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
Where
Palo Alto
Age
1 year to 25 years
People
28
Run by
Stanford University
See details and how to joinNCT06408194
Phase 1Taking people
First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
Where
Aurora, Cincinnati, Fort Worth, Houston, Indianapolis, New York, Philadelphia
Age
18 years and over
People
24
Run by
Allterum Therapeutics, Inc
See details and how to joinNCT07586618
Phase 1Taking people
Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia
Where
Memphis
Age
Up to 21 years
People
60
Run by
St. Jude Children's Research Hospital
See details and how to joinNCT04881240
Phase 1Taking people
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
Where
Memphis
Age
Up to 21 years
People
70
Run by
St. Jude Children's Research Hospital
See details and how to joinNCT07257419
Phase 1Taking people
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Where
Miami
Age
1 day to 21 years
People
65
Run by
Florida International University
See details and how to joinNCT05857969
Phase 1Taking people
Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies
Where
Salt Lake City
Age
18 years and over
People
10
Run by
University of Utah
See details and how to joinNCT06227026